AU7465696A - Synthetic vaccine for protection against human immunodeficiency virus infection - Google Patents
Synthetic vaccine for protection against human immunodeficiency virus infectionInfo
- Publication number
- AU7465696A AU7465696A AU74656/96A AU7465696A AU7465696A AU 7465696 A AU7465696 A AU 7465696A AU 74656/96 A AU74656/96 A AU 74656/96A AU 7465696 A AU7465696 A AU 7465696A AU 7465696 A AU7465696 A AU 7465696A
- Authority
- AU
- Australia
- Prior art keywords
- protection against
- immunodeficiency virus
- virus infection
- human immunodeficiency
- against human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
- 229940126577 synthetic vaccine Drugs 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US546515 | 1995-10-20 | ||
US08/546,515 US5993819A (en) | 1987-09-08 | 1995-10-20 | Synthetic vaccine for protection against human immunodeficiency virus infection |
US59926696A | 1996-02-09 | 1996-02-09 | |
US599266 | 1996-02-09 | ||
PCT/US1996/016911 WO1997014436A1 (en) | 1995-10-20 | 1996-10-18 | Synthetic vaccine for protection against human immunodeficiency virus infection |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU72138/00A Division AU7213800A (en) | 1995-10-20 | 2000-12-08 | Synthetic vaccine for protection against human immunodeficiency virus infection |
Publications (1)
Publication Number | Publication Date |
---|---|
AU7465696A true AU7465696A (en) | 1997-05-07 |
Family
ID=27068273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU74656/96A Abandoned AU7465696A (en) | 1995-10-20 | 1996-10-18 | Synthetic vaccine for protection against human immunodeficiency virus infection |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0868196A4 (en) |
JP (1) | JPH11515006A (en) |
AU (1) | AU7465696A (en) |
CA (1) | CA2235168A1 (en) |
WO (1) | WO1997014436A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814925C2 (en) * | 1998-04-03 | 2000-10-05 | Thomas Harrer | Medicinal products for induction of cytotoxic T cells |
MXPA02007478A (en) * | 2000-02-04 | 2004-08-23 | Univ Duke | Human immunodeficiency virus vaccine. |
US7033593B2 (en) | 2000-09-22 | 2006-04-25 | Duke University | Immunogen comprising an HIV envelope protein, a ligand and H2 peptide |
MXPA03002480A (en) | 2000-09-22 | 2004-05-24 | Univ Duke | Immunogen comprising ligand bound hiv envelpe protein. |
US7195768B2 (en) | 2001-11-07 | 2007-03-27 | Duke University | Polyvalent immunogen |
US7172761B2 (en) | 2001-11-07 | 2007-02-06 | Duke University | Polyvalent immunogen |
CA2466050A1 (en) | 2001-11-07 | 2003-05-15 | Duke University | Polyvalent immunogen |
US20050112139A1 (en) * | 2003-10-23 | 2005-05-26 | Nmk Research, Llc | Immunogenic composition and method of developing a vaccine based on factor H binding sites |
CA2669049A1 (en) * | 2006-11-09 | 2008-11-06 | Sudhir Paul | Binary epitope antibodies and b cell superantigen immune stimulants |
US7892562B2 (en) | 2008-10-08 | 2011-02-22 | Karp Nelson M | Methods of inducing TH-1 immune responses to HIV-1 by administering UV/psoralen-treated desialated inactiviated HIV-1 virions deficient in CD55 and CD59 |
EP3518968B1 (en) | 2016-10-03 | 2022-01-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Hiv-1 env fusion peptide immunogens and their use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0201540B2 (en) * | 1984-10-18 | 2001-10-31 | Institut Pasteur | Envelope antigens of lymphadenopathy associated virus and their applications |
ES2054616T3 (en) * | 1985-12-17 | 1994-08-16 | Akzo Nv | IMMUNOCHEMICAL REAGENT. |
AU617088B2 (en) * | 1986-06-12 | 1991-11-21 | Biogen, Inc. | Peptides involved in the pathogenesis of hiv infection |
US5013548A (en) * | 1987-09-08 | 1991-05-07 | Duke University | Production of antibodies to HIV |
US5019387A (en) * | 1987-09-08 | 1991-05-28 | Duke University | Production of antibodies to HIV |
EP0762895B1 (en) * | 1994-04-29 | 2002-08-07 | Duke University | Synthetic vaccine for protection against human immunodeficiency virus infection |
-
1996
- 1996-10-18 CA CA002235168A patent/CA2235168A1/en not_active Abandoned
- 1996-10-18 JP JP9516093A patent/JPH11515006A/en active Pending
- 1996-10-18 WO PCT/US1996/016911 patent/WO1997014436A1/en not_active Application Discontinuation
- 1996-10-18 AU AU74656/96A patent/AU7465696A/en not_active Abandoned
- 1996-10-18 EP EP96936830A patent/EP0868196A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP0868196A4 (en) | 2004-11-24 |
JPH11515006A (en) | 1999-12-21 |
CA2235168A1 (en) | 1997-04-24 |
WO1997014436A1 (en) | 1997-04-24 |
EP0868196A1 (en) | 1998-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5726694A (en) | Human immunodeficiency virus decoy | |
AU4878096A (en) | Hepatitis b vaccine | |
AU6304996A (en) | Vaccines against hepatitis c | |
AU7557494A (en) | Infection resistant medical devices | |
EP0744192A3 (en) | Fall protection safety suit | |
AU6093296A (en) | Infectious dengue 2 virus pdk-53 as quadravalent vaccine | |
HUP9601466A2 (en) | Adjuvants for viral vaccines | |
LTIP335A (en) | Vaccine for human immunodeficiency virus | |
AU7973994A (en) | Combination therapy for hiv infection | |
HUP9601462A2 (en) | Adjuvants for viral vaccines | |
ZA936592B (en) | Nutrition for persons infected with human immunodeficiency virus | |
NZ310055A (en) | Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection | |
AU7465696A (en) | Synthetic vaccine for protection against human immunodeficiency virus infection | |
AU3154395A (en) | Contraceptive vaccine | |
EP0967993A4 (en) | Anti-cocaine vaccine | |
AU4088697A (en) | Postinfection human immunodeficiency virus (hiv) vaccination therapy | |
AU2769595A (en) | Contraceptive vaccine | |
ZA96722B (en) | Combination therapy for hiv infection | |
AU4602897A (en) | Method for treatment of immunodeficiency virus infection | |
AU4450696A (en) | Enhanced immunogenic vaccine | |
AU1194997A (en) | Plasmid vaccine against pseudorabies virus | |
AU3552797A (en) | Vaccine preparations | |
AU5520796A (en) | Peptide-based vaccine against papillomavirus infection | |
AU5959494A (en) | Vaccines against sterols | |
AU5100696A (en) | Specific hiv-1 group o antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |